Market Overview

Vertex, JNJ's Janssen Enter Agreement for Phase 2 Hepatitis C Study

Related VRTX
Vertex Gets FDA's Priority Review For SNDA For Its ORKAMBI
Short Interest Surges In Illumina And Vertex Pharmaceuticals
FDA accepts Vertex Pharma's application for expanded use of Orkambi; action date September 30 (Seeking Alpha)

Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that it
has entered into a non-exclusive collaboration with Johnson & Johnson's (NYSE: JNJ) Janssen
Pharmaceuticals, Inc. to conduct a Phase 2 proof-of-concept study of an
all-oral regimen for the treatment of hepatitis C containing Vertex's
nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135
and Janssen's protease inhibitor simeprevir (TMC435). As part of the
collaboration, Janssen will conduct a drug-drug interaction study with
VX-135 and simeprevir to support the planned initiation of a Phase 2
proof-of-concept study in early 2013, pending discussions with
regulatory authorities. The Phase 2 study is expected to evaluate
safety, tolerability and viral cure rates using a 12-week combination of
VX-135 and simeprevir. The companies will jointly fund development

See full press release

Posted-In: News Guidance Contracts Management Stock Split Global


Related Articles (VRTX + JNJ)

View Comments and Join the Discussion!